Awareness about the risk of hearing loss after ototoxic treatments in Swiss childhood cancer survivors.
Options
BORIS DOI
Date of Publication
March 27, 2025
Publication Type
Article
Author
Ansari, Marc |
Series
Patient Education and Counseling
ISSN or ISBN (if monograph)
1873-5134
0738-3991
Publisher
Elsevier
Language
English
Publisher DOI
PubMed ID
40179545
Description
Objectives
The International Guideline Harmonization Group recommends childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.Methods
We identified adults diagnosed with cancer < 20 years who received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data were obtained from the ChCR. We used logistic regression to explore factors influencing awareness.Results
Of 424 invited, 105 CCS participated (25 %). Fifty-seven percent did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95 % CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44 % of participants presented clinically relevant hearing loss.Conclusions
Over half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.Practice Implications
Educating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.
The International Guideline Harmonization Group recommends childhood cancer survivors (CCS) exposed to ototoxic treatments be aware of the risk of hearing loss. We assessed awareness among adult CCS.Methods
We identified adults diagnosed with cancer < 20 years who received ototoxic treatments through the Swiss Childhood Cancer Registry (ChCR) and invited them to the HEAR-study. Participants completed a questionnaire and underwent pure-tone audiometry. Cancer and treatment data were obtained from the ChCR. We used logistic regression to explore factors influencing awareness.Results
Of 424 invited, 105 CCS participated (25 %). Fifty-seven percent did not remember receiving information on hearing loss prior to the study. CCS who remembered being informed were more likely diagnosed after 1995 (OR: 4.5, 95 % CI: 1.3-15.4), reported hearing problems (10.9, 2.6-45.1) and other late effects (4.1, 1.3-13.2), and treated with platinum chemotherapy only (10.8, 2.2-53.2) versus cranial radiotherapy only. 44 % of participants presented clinically relevant hearing loss.Conclusions
Over half of CCS exposed to ototoxic treatments were unaware of their risk of hearing loss.Practice Implications
Educating CCS about potential late effects of ototoxic treatments is important to allow early diagnosis and treatment, especially for those who had cancer longer ago and those exposed to cranial radiation.
Funding(s)
File(s)
File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
---|---|---|---|---|---|---|---|
1-s2.0-S0738399125001314-main.pdf | text | Adobe PDF | 1.8 MB | updated |